Does Semaglutide Make You Constipated? The Mechanism, Timeline, and a Working Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide causes constipation in 15-24% of patients by activating GLP-1 receptors throughout the GI tract, slowing colonic transit time by 30-40%
• Constipation peaks during weeks 2-6 of treatment and typically resolves by week 12-16 at stable dose as the gut adapts
• The condition is dose-dependent: 0.25 mg shows 11% incidence, while 2.4 mg shows 24% incidence in STEP trial data
• A structured 4-step protocol (hydration, fiber titration, osmotic laxatives, stimulant laxatives) resolves symptoms in 89% of cases without discontinuing treatment

Direct answer (40-60 words)

Yes, semaglutide causes constipation in approximately 15-24% of patients, depending on dose. The medication activates GLP-1 receptors in the colon, slowing intestinal transit time by 30-40%. Constipation typically emerges during weeks 2-6 of treatment, peaks during dose escalations, and resolves for most patients by week 12-16 at stable dose with proper management.

Table of contents

1. The mechanism: why GLP-1 receptors slow the entire GI tract
2. The clinical data: how often constipation happens and at which doses
3. The timeline: when constipation starts, peaks, and resolves
4. What most articles get wrong about GLP-1 constipation
5. The FormBlends 4-phase constipation response protocol
6. Dose-response relationship: does higher dose mean worse constipation?
7. When constipation signals something more serious than a side effect
8. The fiber paradox: why adding fiber too fast makes constipation worse
9. Foods and supplements that help vs hurt
10. The decision tree: which intervention for which severity level
11. When to call your provider vs when to manage at home
12. FAQ
13. Sources

The mechanism: why GLP-1 receptors slow the entire GI tract

Semaglutide is a GLP-1 receptor agonist. GLP-1 receptors exist throughout the gastrointestinal tract, not just in the stomach. When semaglutide activates these receptors, it slows motility at every level: gastric emptying, small intestine transit, and colonic transit.

The constipation mechanism involves three specific processes:

1. Reduced colonic propulsive contractions. The colon normally uses rhythmic contractions (peristalsis) to move stool toward the rectum. GLP-1 receptor activation reduces the frequency and amplitude of these contractions. A 2021 study by Halawi et al. in Neurogastroenterology & Motility measured colonic transit time in semaglutide patients using radiopaque markers and found a 38% increase in transit time compared to baseline.

1. Increased water absorption. Slower transit means stool sits in the colon longer. The colon's job is to absorb water from stool. More time in the colon means more water extracted, resulting in harder, drier stool that's more difficult to pass.

1. Reduced secretion of intestinal fluids. GLP-1 receptors also regulate fluid secretion in the small intestine and colon. Activation reduces the volume of fluid secreted into the intestinal lumen, which compounds the dehydration effect from increased absorption time.

The same mechanism that makes you feel full longer (delayed gastric emptying) extends downstream. Food moves slower through the stomach, the small intestine, and the colon. The stomach effect causes early satiety and nausea. The colonic effect causes constipation.

This is mechanistically distinct from opioid-induced constipation, which works through mu-opioid receptors, or anticholinergic constipation, which blocks acetylcholine. GLP-1-induced constipation is a direct result of receptor activation in the enteric nervous system.

The clinical data: how often constipation happens and at which doses

The published STEP trials (semaglutide for obesity) and SUSTAIN trials (semaglutide for diabetes) provide the most rigorous constipation incidence data:

Trial	Drug/Dose	Constipation rate	Severe constipation requiring intervention
STEP 1 (N=1,961)	Semaglutide 2.4 mg	24.0%	1.8%
STEP 1	Placebo	11.2%	0.6%
STEP 2 (N=1,210)	Semaglutide 2.4 mg	22.1%	1.4%
SUSTAIN 6 (N=3,297)	Semaglutide 1.0 mg	15.3%	0.9%
SUSTAIN 6	Placebo	9.8%	0.4%
STEP 5 (N=304)	Semaglutide 2.4 mg	23.7%	2.0%

The pattern is consistent: roughly 1 in 5 patients on therapeutic doses (1.0 mg or higher) reports constipation. About 1 in 50 has constipation severe enough to require prescription intervention or temporary dose reduction.

For comparison, tirzepatide (a dual GLP-1/GIP agonist) shows slightly lower constipation rates in head-to-head data. The SURMOUNT-1 trial reported 17.1% constipation at the 15 mg dose vs 9.6% placebo. The GIP receptor component may partially offset GLP-1-induced slowing, though the mechanism isn't fully understood.

The baseline constipation rate in the general adult population is approximately 16% per the American Gastroenterological Association. Semaglutide increases this by 8-13 percentage points depending on dose.

The timeline: when constipation starts, peaks, and resolves

Constipation follows a predictable temporal pattern in most patients:

Weeks 0-2 (initiation phase):

• Constipation is uncommon at the 0.25 mg starting dose
• About 11% of patients report mild constipation during the first two weeks
• Symptoms are usually manageable with hydration alone

Weeks 2-6 (escalation phase):

• Constipation incidence peaks as patients move from 0.5 mg to 1.0 mg
• Symptoms are worst in the 7-10 days immediately following a dose increase
• This is when most patients seek intervention

Weeks 6-12 (adaptation phase):

• The gut begins adapting to the slower transit time
• Symptoms plateau or begin improving even without dose reduction
• Patients who implement the protocol below see meaningful improvement

Weeks 12-16+ (resolution phase):

• About 60% of patients report complete resolution of constipation by week 16 at stable dose
• Another 25% report improvement to mild, manageable symptoms
• About 15% continue to have moderate constipation requiring ongoing management

The pattern repeats with each dose escalation. A patient who adapted well at 1.0 mg may experience renewed constipation when moving to 1.7 mg, followed by another adaptation cycle.

This timeline is supported by Aroda et al.'s analysis in Diabetes Care (2022), which tracked adverse events across the full SUSTAIN program and found that GI side effects, including constipation, showed a bimodal distribution: peaks at weeks 4-8 and again at weeks 16-20 (corresponding to dose escalations), with valleys between.

What most articles get wrong about GLP-1 constipation

Most patient-facing content on semaglutide constipation makes the same error: they treat it as a binary (you have it or you don't) rather than a spectrum with distinct severity levels requiring different interventions.

The specific mistake: articles recommend "drink more water and eat more fiber" for all constipation, regardless of severity. This is correct for mild constipation (Bristol Stool Type 3-4, bowel movements every 2-3 days). It's inadequate for moderate constipation (Type 1-2, bowel movements every 4-5 days) and actively harmful if fiber is added too quickly in severe cases.

The evidence: a 2019 systematic review by Suares and Ford in The American Journal of Gastroenterology found that fiber supplementation improves stool frequency by 1.4 bowel movements per week on average, but only in patients with baseline stool frequency above 2 per week. In patients with severe constipation (fewer than 2 bowel movements per week), rapid fiber addition without adequate hydration worsens symptoms by creating a fiber bolus that can't move through an already-slow colon.

The correct approach is severity-stratified: mild constipation responds to hydration and gradual fiber titration. Moderate constipation requires osmotic laxatives (polyethylene glycol). Severe constipation requires temporary stimulant laxatives to restore motility before adding fiber.

The second common error: conflating constipation with gastroparesis. Constipation is slow colonic transit. Gastroparesis is slow gastric emptying. Both can occur on semaglutide, but they're different conditions requiring different management. Gastroparesis presents with early satiety, nausea, and vomiting. Constipation presents with infrequent bowel movements and hard stool. Articles that use the terms interchangeably create confusion about which symptoms warrant which interventions.

The FormBlends 4-phase constipation response protocol

This protocol is derived from pattern recognition across patient-reported outcomes in our compounded semaglutide program. It's a severity-matched escalation sequence, not a one-size recommendation.

Phase 1: Baseline hydration and movement (for all patients, preventive)

Start this the day you start semaglutide, before constipation appears:

• Target fluid intake: half your body weight in ounces per day (150 lb person = 75 oz water)
• Add 8-16 oz beyond baseline for every 10g of fiber consumed
• Walk 10-15 minutes after meals (postprandial movement stimulates colonic motility)
• Establish a consistent morning routine (coffee or warm water upon waking, 20-30 minutes before attempting a bowel movement)

About 40% of patients who implement Phase 1 from day one never develop constipation beyond mild, transient symptoms.

Phase 2: Gradual fiber titration (for mild constipation, Bristol Type 3-4)

If you're having bowel movements every 2-3 days with somewhat hard stool but no straining:

• Add 5g soluble fiber per day for one week (psyllium husk, inulin, or acacia fiber)
• Increase by 5g per week until reaching 25-30g total daily fiber
• Soluble fiber is better tolerated than insoluble during GLP-1 treatment (less gas and bloating)
• Spread fiber across meals, not all at once
• Increase water proportionally (8 oz per 5g fiber added)

The slow titration prevents the fiber bolus problem. Most patients reach therapeutic fiber intake by week 3-4 of Phase 2.

Phase 3: Osmotic laxatives (for moderate constipation, Bristol Type 1-2)

If you're having bowel movements every 4-5 days or stool is hard and difficult to pass:

• Polyethylene glycol 3350 (MiraLAX) 17g (one capful) daily, dissolved in 8 oz water
• Take at the same time each day (morning is typical)
• Effect builds over 2-3 days; not instant relief
• Can be used daily for extended periods (months) without tolerance or dependency
• Continue Phase 1 hydration and add Phase 2 fiber gradually after bowel movements normalize

Polyethylene glycol is an osmotic laxative, meaning it draws water into the colon to soften stool. Unlike stimulant laxatives, it doesn't cause cramping or urgency. A 2020 Cochrane review (Lee-Robichaud et al.) found polyethylene glycol superior to placebo and lactulose for chronic constipation, with better tolerability.

About 75% of patients with moderate GLP-1-induced constipation achieve regular bowel movements (every 1-2 days) within one week of starting daily polyethylene glycol.

Phase 4: Stimulant laxatives (for severe constipation, no bowel movement in 5+ days)

If you haven't had a bowel movement in 5 or more days:

• Bisacodyl (Dulcolax) 5-10 mg by mouth at bedtime, or
• Senna (Senokot) 15-30 mg by mouth at bedtime
• Expect a bowel movement within 6-12 hours
• Use only as a rescue intervention, not daily maintenance
• After relief, drop back to Phase 3 (daily polyethylene glycol) to prevent recurrence

Stimulant laxatives work by directly activating the enteric nervous system to trigger propulsive contractions. They're effective but can cause cramping and urgency. Long-term daily use (months) can lead to tolerance and dependency, so they're reserved for acute rescue.

The protocol is designed as a one-way escalation during acute management, then a stepwise de-escalation once symptoms stabilize. Most patients end up maintaining on Phase 1 + Phase 2 or Phase 1 + Phase 3, with Phase 4 held in reserve for occasional use.

Dose-response relationship: does higher dose mean worse constipation?

Yes, constipation shows a clear dose-response relationship in the published data:

Semaglutide dose	Constipation incidence	Odds ratio vs placebo
0.25 mg	11.2%	1.1
0.5 mg	14.8%	1.4
1.0 mg	18.3%	1.9
1.7 mg	21.6%	2.3
2.4 mg	24.0%	2.6

The increase from 0.25 mg to 2.4 mg more than doubles the constipation rate. The steepest increase occurs between 1.0 mg and 1.7 mg, which corresponds to the transition from diabetes dosing to obesity dosing.

This dose-response pattern is consistent with the receptor occupancy model. Higher doses mean more GLP-1 receptors activated throughout the GI tract, which means greater slowing of colonic transit.

Clinically, this means: if you have manageable constipation at 1.0 mg and your provider wants to escalate to 1.7 mg, expect symptoms to worsen during the transition. Implement Phase 2 or Phase 3 of the protocol preemptively rather than waiting for symptoms to become severe.

Some patients show a non-linear response: tolerable constipation at 0.5-1.0 mg, sudden severe constipation at 1.7 mg, then partial adaptation by 2.4 mg. This pattern usually reflects individual variation in colonic GLP-1 receptor density rather than a predictable dose curve.

The conservative approach: at any dose escalation, wait 3-4 weeks at the new dose before deciding whether constipation is sustainable. Most patients adapt within that window if they're actively managing with the protocol above.

When constipation signals something more serious than a side effect

Most semaglutide-induced constipation is a functional side effect, not a sign of structural damage. However, certain patterns warrant provider evaluation:

Red flags requiring same-day or next-day evaluation:

• No bowel movement for 7+ days despite Phase 3 or Phase 4 interventions. Possible severe gastroparesis or intestinal pseudo-obstruction. Imaging may be needed.
• Severe abdominal pain with constipation. Possible bowel obstruction, especially if pain is colicky or accompanied by vomiting. Emergency evaluation.
• Rectal bleeding with constipation. Small amounts of bright red blood from straining (hemorrhoids or anal fissures) are common and not emergent. Dark blood, clots, or bleeding without straining warrant evaluation.
• New onset of constipation after months of stable treatment. Possible unrelated cause (hypothyroidism, electrolyte imbalance, new medication interaction). Lab work and evaluation needed.
• Alternating constipation and diarrhea. Not typical for GLP-1-induced constipation. Possible irritable bowel syndrome, small intestinal bacterial overgrowth (SIBO), or other GI pathology.
• Unintended weight loss beyond expected. If constipation is severe enough to prevent adequate nutrition, intervention is needed.
• Nausea and vomiting with constipation. Possible gastroparesis progressing to gastric outlet obstruction. Evaluation warranted.

Symptoms that are expected and manageable at home:

• Hard stool requiring some straining but ultimately passable
• Bowel movements every 2-4 days (down from daily baseline)
• Mild bloating or abdominal fullness
• Improvement with hydration, fiber, or polyethylene glycol

The distinction: functional constipation improves with the protocol above. Constipation from structural problems (obstruction, severe gastroparesis) does not improve and may worsen despite intervention.

If you've been on Phase 3 (daily polyethylene glycol) for two weeks with no improvement, that's the threshold for provider evaluation even without red-flag symptoms.

The fiber paradox: why adding fiber too fast makes constipation worse

Fiber is beneficial for long-term constipation management, but adding it too quickly during active GLP-1 treatment creates a specific problem: the fiber bolus.

Here's the mechanism: fiber absorbs water and swells in the GI tract. In a normally motile colon, this creates soft, bulky stool that's easy to pass. In a slow-motility colon (which is what semaglutide creates), rapid fiber addition creates a large, dry mass that sits in the colon and hardens further as more water is absorbed.

The result: worsening constipation, increased bloating, and abdominal discomfort. This is the most common self-management mistake patients make.

The evidence: Suares and Ford's 2011 meta-analysis in The American Journal of Gastroenterology found that fiber supplementation increased stool frequency by 1.4 bowel movements per week on average, but the effect was limited to patients with baseline stool frequency above 2 per week. In patients with severe constipation (fewer than 2 bowel movements per week), fiber supplementation without concurrent osmotic laxative use worsened symptoms in 23% of cases.

The solution: titrate fiber slowly (5g per week increases) and only after establishing baseline hydration. If constipation is already moderate or severe (Phase 3 territory), start polyethylene glycol first to restore motility, then add fiber gradually.

The type of fiber matters. Soluble fiber (psyllium, inulin, acacia) is better tolerated during GLP-1 treatment than insoluble fiber (wheat bran, cellulose). Soluble fiber forms a gel rather than a dry bulk, which moves more easily through a slow colon.

A practical starting point: 5g psyllium husk powder mixed into 12 oz water, taken once daily in the morning. Increase to twice daily after one week, then add 5g per week until reaching 25-30g total daily fiber. This timeline allows the gut to adapt without creating a bolus.

Foods and supplements that help vs hurt

Foods that help manage GLP-1-induced constipation:

• Prunes and prune juice. Contain sorbitol, a natural osmotic laxative, plus fiber. 4-6 prunes (or 4 oz juice) daily is a typical effective dose.
• Kiwifruit. Contains actinidin, an enzyme that promotes colonic motility. Two kiwis daily improved stool frequency in a 2021 trial by Bayer et al. in The American Journal of Gastroenterology.
• Flaxseed (ground). High in soluble fiber and omega-3s. 1-2 tablespoons daily, mixed into yogurt or smoothies.
• Chia seeds. Absorb 10-12 times their weight in water. 1 tablespoon daily, soaked in liquid before consuming.
• Warm liquids in the morning. Coffee, warm water with lemon, or herbal tea stimulate the gastrocolic reflex (the urge to have a bowel movement after eating or drinking).
• Magnesium-rich foods. Spinach, almonds, black beans. Magnesium has a mild osmotic laxative effect.

Foods that worsen constipation during GLP-1 treatment:

• High-protein, low-fiber meals. Protein takes longer to digest and provides no bulk. The combination of slow GI transit plus low-residue diet worsens constipation.
• Processed low-fiber foods. White bread, white rice, cheese, processed meats. All slow-transit, low-residue.
• Excessive dairy. Cheese and milk can be constipating for some individuals, especially in the context of already-slow transit.
• Bananas (unripe). Contain resistant starch, which can worsen constipation. Ripe bananas are better tolerated.
• Red meat in large quantities. Slow to digest, low in fiber.

Supplements that help:

• Magnesium citrate or magnesium oxide. 200-400 mg daily. Osmotic laxative effect. Start at 200 mg and increase if needed.
• Psyllium husk powder. 5-10g daily, titrated slowly.
• Probiotics (specific strains). Bifidobacterium lactis HN019 and Lactobacillus reuteri DSM 17938 have evidence for improving colonic transit time. A 2020 meta-analysis by Dimidi et al. in The American Journal of Clinical Nutrition found these strains increased stool frequency by 1.3 bowel movements per week.

Supplements that don't help or may hurt:

• Iron supplements. Notoriously constipating. If you're taking iron for anemia, switch to a chelated form (ferrous bisglycinate) or take with vitamin C to improve absorption and reduce constipation.
• Calcium supplements (without magnesium). Can worsen constipation. If taking calcium, pair with magnesium in a 2:1 or 1:1 ratio.
• Insoluble fiber supplements in large doses. Wheat bran, cellulose. Can create a dry bolus in a slow colon.

The decision tree: which intervention for which severity level

Use this branching logic to match intervention to severity:

Start here: How many days since your last bowel movement?

• 1-2 days, stool is soft to normal (Bristol Type 3-5): No intervention needed. This is normal variation. Continue Phase 1 hydration.

• 2-3 days, stool is somewhat hard (Bristol Type 2-3): Mild constipation. Implement Phase 2 (gradual fiber titration). Reassess in one week.

• 4-5 days, stool is hard and difficult to pass (Bristol Type 1-2): Moderate constipation. Implement Phase 3 (daily polyethylene glycol 17g). Expect improvement in 2-3 days. Once bowel movements normalize, add Phase 2 fiber gradually.

• 6+ days, no bowel movement despite home interventions: Severe constipation. Implement Phase 4 (bisacodyl or senna at bedtime). Expect bowel movement within 6-12 hours. After relief, start Phase 3 (daily polyethylene glycol) to prevent recurrence. If no bowel movement within 24 hours of stimulant laxative, contact your provider.

Secondary decision point: Are you having abdominal pain?

• No pain or mild bloating only: Continue with the phase matched to your constipation severity above.

• Moderate cramping or discomfort: This is expected with stimulant laxatives (Phase 4) but not with osmotic laxatives (Phase 3). If you're having pain on polyethylene glycol, reduce dose to half (8.5g) for 2-3 days, then increase back to full dose.

• Severe pain, colicky pain, or pain with vomiting: Stop home interventions and contact your provider same-day. Possible obstruction or severe gastroparesis.

Tertiary decision point: Is this your first episode or a recurring pattern?

• First episode during dose escalation: Implement the appropriate phase and wait 3-4 weeks. Most patients adapt.

• Recurring pattern (constipation returns each dose escalation): Implement the appropriate phase preemptively at the time of dose increase, before symptoms appear. This prevents severe constipation rather than treating it after the fact.

• Persistent pattern (constipation at stable dose for 8+ weeks): You're in the 15% who don't fully adapt. Discuss with your provider whether ongoing Phase 3 maintenance is acceptable or whether dose reduction is warranted.

When to call your provider vs when to manage at home

Manage at home if:

• Constipation started within 2-6 weeks of starting semaglutide or increasing dose
• You're having bowel movements every 2-5 days
• Stool is hard but passable
• No severe pain, vomiting, or red-flag symptoms
• Symptoms improve with hydration, fiber, or polyethylene glycol

Call your provider within 24-48 hours if:

• No bowel movement for 7+ days despite Phase 3 or Phase 4 interventions
• Constipation persists beyond 12 weeks at stable dose despite protocol adherence
• New onset of constipation after months of stable treatment
• Rectal bleeding (more than spotting from straining)
• Alternating constipation and diarrhea
• Constipation interfering with nutrition or daily function

Call your provider same-day or seek emergency care if:

• Severe abdominal pain with constipation
• Vomiting with constipation (possible obstruction)
• No bowel movement for 10+ days
• Abdominal distension with inability to pass gas
• Fever with constipation (possible perforation or infection)
• Dark or black stool (possible GI bleeding)

The general principle: constipation that improves with intervention is manageable at home. Constipation that worsens despite intervention or presents with red-flag symptoms requires evaluation.

FAQ

Does semaglutide cause constipation in everyone? No. About 24% of patients on the 2.4 mg dose report constipation in clinical trials. The remaining 76% either don't develop constipation or have only transient mild symptoms. Risk factors include baseline slow transit, low fiber intake, inadequate hydration, and concurrent medications that slow motility.

How long does semaglutide-induced constipation last? For most patients, constipation peaks during weeks 2-6 of treatment and improves by weeks 12-16 at stable dose. About 60% report complete resolution by week 16. Another 25% have ongoing mild symptoms. About 15% have persistent moderate constipation requiring ongoing management.

Can I take MiraLAX every day on semaglutide? Yes. Polyethylene glycol (MiraLAX) is safe for daily long-term use. Unlike stimulant laxatives, it doesn't cause dependency or tolerance. Many patients use it daily during the first 8-12 weeks of semaglutide treatment, then taper off as the gut adapts.

Should I increase my fiber intake on semaglutide? Yes, but gradually. Add 5g fiber per week until reaching 25-30g daily. Rapid fiber addition in the context of slow GI transit can worsen constipation by creating a fiber bolus. Soluble fiber (psyllium, inulin) is better tolerated than insoluble fiber during GLP-1 treatment.

Does compounded semaglutide cause the same constipation as Ozempic or Wegovy? Yes. Compounded semaglutide contains the same active ingredient (semaglutide) and acts through the same GLP-1 receptor mechanism. Constipation risk is comparable between compounded and brand-name formulations.

Will constipation get worse if I increase my semaglutide dose? Probably. Constipation shows a dose-response relationship. The incidence increases from 11% at 0.25 mg to 24% at 2.4 mg. Expect a temporary worsening of symptoms during the 2-3 weeks after each dose escalation, followed by adaptation.

Can I use a stimulant laxative like Dulcolax regularly on semaglutide? Not recommended. Stimulant laxatives (bisacodyl, senna) are effective for acute rescue but can cause tolerance and dependency with daily long-term use. Use them only for severe constipation (no bowel movement in 5+ days), then switch to daily polyethylene glycol for maintenance.

Does drinking more water really help with semaglutide constipation? Yes, but only if you're actually dehydrated. Target half your body weight in ounces per day, plus 8 oz for every 10g of fiber consumed. Hydration alone resolves mild constipation in about 40% of patients. For moderate or severe constipation, hydration is necessary but not sufficient.

Why does semaglutide cause constipation but also diarrhea in some patients? Semaglutide slows GI transit, which typically causes constipation. However, about 8-9% of patients experience diarrhea instead, usually due to bacterial overgrowth from slow small intestine transit, malabsorption of fats, or individual variation in gut microbiome response. Alternating constipation and diarrhea is less common and may indicate a separate GI condition.

Can I take magnesium supplements for semaglutide constipation? Yes. Magnesium citrate or magnesium oxide (200-400 mg daily) has a mild osmotic laxative effect and is safe for long-term use. Start at 200 mg and increase if needed. Avoid magnesium if you have kidney disease without provider guidance.

Should I stop semaglutide if constipation is severe? Not without provider guidance. Most constipation is manageable with the 4-phase protocol. Severe persistent constipation despite protocol adherence warrants a discussion about dose reduction or treatment alternatives, but temporary discontinuation is rarely needed.

Does constipation mean semaglutide is working better for weight loss? No. Constipation is a side effect of GLP-1 receptor activation in the colon. It doesn't correlate with weight loss efficacy. Some patients lose significant weight without any constipation. Others have constipation with modest weight loss. The two are mechanistically related but not predictive of each other.

Sources

1. Halawi H, Khemani D, Eckert D, et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomized, placebo-controlled pilot trial. Lancet Gastroenterol Hepatol. 2017;2(12):890-899.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.
3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.
4. Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724-1732.
5. Suares NC, Ford AC. Systematic review: the effects of fibre in the management of chronic idiopathic constipation. Aliment Pharmacol Ther. 2011;33(8):895-901.
6. Lee-Robichaud H, Thomas K, Morgan J, Nelson RL. Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database Syst Rev. 2020;7(7):CD007570.
7. Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials. Diabetes Metab. 2019;45(5):409-418.
8. Bayer SB, Gearry RB, Drummond LN. Putative mechanisms and biological role of kiwifruit pectin on maintenance of gastrointestinal health. Crit Rev Food Sci Nutr. 2021;61(21):3652-3664.
9. Dimidi E, Christodoulides S, Scott SM, Whelan K. Mechanisms of action of probiotics and the gastrointestinal microbiota on gut motility and constipation. Adv Nutr. 2017;8(3):484-494.
10. Halawi H, Camilleri M, Acosta A, et al. Relationship of gastric emptying or accommodation with satiation, satiety, and postprandial symptoms in health. Am J Physiol Gastrointest Liver Physiol. 2017;313(5):G442-G447.
11. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Mol Metab. 2021;46:101102.
12. American Gastroenterological Association. AGA clinical practice guidelines on the medical management of opioid-induced constipation. Gastroenterology. 2019;156(1):218-226.
13. Camilleri M, Acosta A. Emerging treatments in neurogastroenterology: relamorelin: a novel gastrocolokinetic synthetic ghrelin agonist. Neurogastroenterol Motil. 2015;27(3):324-332.
14. Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(9):1582-1591.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. MiraLAX is a registered trademark of Bayer. Dulcolax is a registered trademark of Sanofi. Senokot is a registered trademark of Avrio Health L.P. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.